Pharmacokinetics of Tablet and Liquid Formulations of Oral 6-mercaptopurine in Children with Acute Lymphoblastic Leukemia

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 2020 Jun 11

PMID 32519032

Citations 4

Authors

Rikke Hebo Larsen

Lisa Lyngsie Hjalgrim

Kathrine Grell

Kim Kristensen

Line Gerner Pedersen

Emilie Damgaard Brunner

Bodil Als-Nielsen

Kjeld Schmiegelow

Jacob Nersting

Affiliations

Soon will be listed here.

Abstract

Purpose: Mercaptopurine (6MP) is essential to cure childhood acute lymphoblastic leukemia (ALL). A liquid 6MP formulation was recently introduced to facilitate oral 6MP administration, especially to children. Its approval and bioequivalence with 6MP tablet were based on comparative pharmacokinetics in 60 healthy adults. Due to potential pharmacokinetic differences between healthy adults and children with ALL, we compared pharmacokinetics of tablet and liquid 6MP formulations in children with ALL.

Methods: Pharmacokinetics of 50 mg 6MP tablet (Puri-Nethol) and 20 mg/ml 6MP liquid suspension (Xaluprine) were compared in a non-blinded, random order, single-dose, cross-over study in 16 children with ALL (eight males). 6MP was administered after a 12 h fast, and 6MP plasma concentrations measured consecutively over seven hours post-dose. Pharmacokinetic outcomes were as follows: Area under the curve (AUC), maximum plasma concentration (C), time to maximum plasma concentration (T), and terminal half-life (T).

Results: Liquid 6MP formulation resulted in a 26% lower AUC (p = 0.02) compared with tablet (median 1215 vs. 1805 h × nmol/l). No significant differences were observed for CT and T (p = 0.28, p = 0.09, p = 0.41, respectively). Based on criteria declared by the World Health Organization the results did not establish non-inferiority of liquid 6MP formulation compared with 6MP tablet.

Conclusion: Non-inferiority of liquid 6MP formulation compared with 6MP tablet was not demonstrated. Yet, maintenance therapy doses are adjusted by degree of myelosuppression and not by 6MP dose. Thus, in spite of a lower bioavailability, a liquid 6MP formulation is still desirable in a clinical setting, especially for children. However, if shifting between 6MP formulation is indicated, dose adjustments should be anticipated to maintain equivalent treatment intensity in children with ALL. The study is registered on clinicaltrials.gov (NCT01906671). Date of registration: 24.07.13.

Citing Articles

Functional comparison of human and murine equilibrative nucleobase transporter 1.

Kim C, Sayler A, Dean H, Ruel N, Hammond J PLoS One. 2024; 19(10):e0311519.

PMID: 39361655 PMC: 11449324. DOI: 10.1371/journal.pone.0311519.

Maintenance Treatment in Acute Lymphoblastic Leukemia: A Clinical Primer.

Krishnan S, Mahadevan A, Mungle T, Gogoi M, Saha V Indian J Pediatr. 2023; 91(1):47-58.

PMID: 37493925 DOI: 10.1007/s12098-023-04687-6.

Integration of Biorelevant Pediatric Dissolution Methodology into PBPK Modeling to Predict In Vivo Performance and Bioequivalence of Generic Drugs in Pediatric Populations: a Carbamazepine Case Study.

Pawar G, Wu F, Zhao L, Fang L, Burckart G, Feng K AAPS J. 2023; 25(4):67.

PMID: 37386339 DOI: 10.1208/s12248-023-00826-1.

Advances in Thiopurine Drug Delivery: The Current State-of-the-Art.

Bayoumy A, Crouwel F, Chanda N, Florin T, Buiter H, Mulder C Eur J Drug Metab Pharmacokinet. 2021; 46(6):743-758.

PMID: 34487330 PMC: 8599251. DOI: 10.1007/s13318-021-00716-x.

References

Toft N, Birgens H, Abrahamsson J, Griskevicius L, Hallbook H, Heyman M . Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2017; 32(3):606-615. DOI: 10.1038/leu.2017.265. View

Hunger S, Mullighan C . Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2015; 373(16):1541-52. DOI: 10.1056/NEJMra1400972. View

Pieters R, de Groot-Kruseman H, van der Velden V, Fiocco M, van den Berg H, de Bont E . Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. J Clin Oncol. 2016; 34(22):2591-601. DOI: 10.1200/JCO.2015.64.6364. View

Dores G, Devesa S, Curtis R, Linet M, Morton L . Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood. 2011; 119(1):34-43. PMC: 3251235. DOI: 10.1182/blood-2011-04-347872. View

Schmiegelow K, Nielsen S, Frandsen T, Nersting J . Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol. 2014; 36(7):503-17. PMC: 4222610. DOI: 10.1097/MPH.0000000000000206. View

Toyoda Y, Manabe A, Tsuchida M, Hanada R, Ikuta K, Okimoto Y . Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol. 2000; 18(7):1508-16. DOI: 10.1200/JCO.2000.18.7.1508. View

Riehm H, Gadner H, Henze G, Kornhuber B, Lampert F, Niethammer D . Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematol Blood Transfus. 1990; 33:439-50. DOI: 10.1007/978-3-642-74643-7_81. View

Nygaard Nielsen S, Grell K, Nersting J, Abrahamsson J, Lund B, Kanerva J . DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial. Lancet Oncol. 2017; 18(4):515-524. DOI: 10.1016/S1470-2045(17)30154-7. View

Bhatia S, Landier W, Shangguan M, Hageman L, Schaible A, Carter A . Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group. J Clin Oncol. 2012; 30(17):2094-101. PMC: 3601449. DOI: 10.1200/JCO.2011.38.9924. View

10.

Kato M, Ishimaru S, Seki M, Yoshida K, Shiraishi Y, Chiba K . Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children. Leukemia. 2016; 31(3):580-584. DOI: 10.1038/leu.2016.274. View

11.

Zimm S, Collins J, Riccardi R, ONeill D, Narang P, Chabner B . Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered?. N Engl J Med. 1983; 308(17):1005-9. DOI: 10.1056/NEJM198304283081705. View

12.

Lennard L, Keen D, Lilleyman J . Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations. Clin Pharmacol Ther. 1986; 40(3):287-92. DOI: 10.1038/clpt.1986.178. View

13.

Sulh H, Koren G, Whalen C, Soldin S, Zipursky A, Greenberg M . Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia. Clin Pharmacol Ther. 1986; 40(6):604-9. DOI: 10.1038/clpt.1986.233. View

14.

Mulla H, Leary A, White P, Pandya H . A step toward more accurate dosing for mercaptopurine in childhood acute lymphoblastic leukemia. J Clin Pharmacol. 2011; 52(10):1610-3. DOI: 10.1177/0091270011423663. View

15.

Frandsen T, Heyman M, Abrahamsson J, Vettenranta K, Asberg A, Vaitkeviciene G . Complying with the European Clinical Trials directive while surviving the administrative pressure - an alternative approach to toxicity registration in a cancer trial. Eur J Cancer. 2013; 50(2):251-9. DOI: 10.1016/j.ejca.2013.09.027. View

16.

Toft N, Birgens H, Abrahamsson J, Bernell P, Griskevicius L, Hallbook H . Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol. Eur J Haematol. 2013; 90(5):404-12. DOI: 10.1111/ejh.12097. View

17.

Arico M, Baruchel A, Bertrand Y, Biondi A, Conter V, Eden T . The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29--30, 2005. Leukemia. 2005; 19(7):1145-52. DOI: 10.1038/sj.leu.2403783. View

18.

Schmiegelow K, Nersting J, Nygaard Nielsen S, Heyman M, Wesenberg F, Kristinsson J . Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?. Pediatr Blood Cancer. 2016; 63(12):2104-2111. DOI: 10.1002/pbc.26139. View

19.

Koren G, FERRAZINI G, Sulh H, Langevin A, Kapelushnik J, Klein J . Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children. N Engl J Med. 1990; 323(1):17-21. DOI: 10.1056/NEJM199007053230104. View

20.

Karran P, Attard N . Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer. 2007; 8(1):24-36. DOI: 10.1038/nrc2292. View